ISO ISOPLEXIS CORP

IsoPlexis to Participate in the Morgan Stanley Global Healthcare Conference

IsoPlexis to Participate in the Morgan Stanley Global Healthcare Conference

BRANFORD, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

IsoPlexis’ management is scheduled to participate in a fireside chat on Monday, September 12th at 4:50 p.m. Eastern Time / 1:50 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: .

About IsoPlexis

IsoPlexis is empowering labs, changing the course of human health.

By leading the discovery and identification of how multi-functional immune cells communicate and respond, IsoPlexis assists researchers in understanding and predicting disease progression, treatment resistance and therapeutic efficacy.

IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies by revenue and 78% of leading U.S. comprehensive cancer centers.

Investor Contact

Press Contact



EN
31/08/2022

Underlying

ISOISOPLEXIS CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ISOPLEXIS CORP

 PRESS RELEASE
Free
ISO ISOPLEXIS CORP

IsoPlexis Reports Preliminary Full Year 2022 Revenue

IsoPlexis Reports Preliminary Full Year 2022 Revenue BRANFORD, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended December 31, 2022. Total revenue for the full year ended December 31, 2022 is expected to be in the range of $16.6 to $16.8 million, representing a decrease of approximately 3% to 4% compared to $17.3 million for the full year ended December 31, 2021. Fourth quarter results were l...

January 12, 2023 1 EN
 PRESS RELEASE
Free
ISO ISOPLEXIS CORP

Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Ce...

Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (Nasdaq: BLI), a life sciences tools company, and IsoPlexi...

December 21, 2022 1 EN
 PRESS RELEASE
Free
ISO ISOPLEXIS CORP

IsoPlexis Reports Third Quarter 2022 Financial Results

IsoPlexis Reports Third Quarter 2022 Financial Results BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended September 30, 2022. Recent Highlights Revenue of $4.5 million for the third quarter 2022, representing a 7% increase from the corresponding period of 2021Sold 23 new instruments in the third quarter, bringing cumulative instruments sold to 277Reduced total operating expenses by 27% from the prior...

November 10, 2022 1 EN
 PRESS RELEASE
Free
ISO ISOPLEXIS CORP

IsoPlexis to Participate in Upcoming Investor Conferences

IsoPlexis to Participate in Upcoming Investor Conferences BRANFORD, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the following investor conferences. Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, New York, NYMulti-Omics Panel on Thursday, November 17th at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time Evercore ISI HealthCONx Conference, VirtualFireside Chat on Thursday, December 1st a...

November 9, 2022 1 EN
 PRESS RELEASE
Free
ISO ISOPLEXIS CORP

IsoPlexis to Report Third Quarter 2022 Financial Results on November 1...

IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022 BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section ...

October 19, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch